IBD Market Snapshot: Payers May Shift Preferred Products To Accommodate New Drugs

Head-To-Head Studies Are Few, But Data Could Change Positioning

Multi-product players may be able to use bundled rebates for preferred formulary status and biosimilars offer a new competitive dynamic, but there is hope for novel therapies.

IBD on a blue background with medical neon icons, medical background with a microscope, science, research
Payer preferences in IBD could shuffle as new data emerge • Source: Shutterstock

A slate of new mechanisms are emerging in inflammatory bowel disease (IBD), and with new ulcerative colitis (UC) and Crohn’s Disease (CD) data and products emerging in the space, change may be coming to payer formularies dominated by anti-TNF antibodies and other biologics used as advanced therapies after patients progress on initial conventional therapies.

Companies that already have multiple IBD products on the market, including Humira (adalimumab) marketer AbbVie Inc., may be able...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Alimentary/Metabolic

More from Therapeutic Category